Nippon India Pharma Fund - Direct (G) vs Tata Value Fund - Direct (G)

Nippon India Pharma Fund - Direct (G) vs Tata Value Fund - Direct (G)

stock1

Nippon India Pharma Fund - Direct (G)

7.4%

stock2

Tata Value Fund - Direct (G)

0.96%

Loading chart...

About Fund

Deutsche Bank AG

Karvy Computershare Pvt. Ltd.

Deutsche Bank HDFC CitiBank N.A. Standard Chartered Bank

CAMS Ltd. Karvy Computershare P Ltd MCS Ltd.

Very High Risk

5000

9044.23

1.12

634.5023

January 1, 2013

1

Very High Risk

5000

8341.71

1.77

394.8686

January 1, 2013

0

14.01 %

19.35 %

7.4 %

15.52 %

14.03 %

0.96 %

Sailesh Raj Bhan

MBA (Finance), CFA.

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Atul Bhole

B.com., CA (Final) MMS (JBIMS)

Mr. Atul has over 18 years of experience in Indian equity markets. Prior to joining KMAMC, he has worked with DSP Asset Managers as SVP- Investments and Tata Asset Management Pvt Ltd as Fund Manager and Research analyst. He has also worked as research analyst in JP Morgan Services (India) Pvt. Ltd. and with State Bank of India. a

Bhupinder Sethi

B.E, MBA

He joined TATA Amc in march 2005 prior to this he worked as fund manager at dundee mutual fund from feb 2000 to dec 2002 and as vice-presidend investments at Jacob Ballas Capital India.

Sonam Udasi

B.Com, PGDM-Finance

Prior to joining Tata AMC he was associated with ASK Raymond James (Jun 2005-Jan 2006) as Lead Analyst (Reporting to Head Research), JM Financial AMC (Feb 2006-June 2007) as Senior Analyst (Reporting to CIO), Prime Securities (Aug 2007-Oct 2008) as Head Research (Reporting to President), BRICS Securities (Nov 2008-Apr 2010) as Consumer Vertical (Reporting to Head Equities) and IDBI Capital Market Services Ltd (Jun 2010-March 2014) as Head Research (Reporting to Executive VP).

Get your FAQs right